In the 11 ALK-DLBCL pediatric cases, all regimens used were highly intensive (i.e. BFM90 [35], LMB89 [36], LMB96 [37], POG8719 [38]). This evidence concerns the gene ALK and diffuse large B-cell lymphoma.